OncoMatch/Clinical Trials/NCT07632638
Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedures
Is NCT07632638 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies RonovoTM Robotic Surgical Platform for malignant neoplasms.
Treatment: RonovoTM Robotic Surgical Platform — CONSTELAR is a prospective, single-arm, multi-specialty registry designed to evaluate the safety and intraoperative performance of the RonovoTM robotic surgical platform in adult patients undergoing elective oncological surgery. The study enrolls patients across four surgical specialties (Digestive Surgery, Thoracic Surgery, Urology, and Gynecology) at a single academic center. Primary endpoints include 30-day and 90-day complication rates (Clavien-Dindo classification), operative times, conversion rates, estimated blood loss, and device-related technical failures. Secondary endpoints encompass length of hospital stay, Intensive Care Unit (ICU) admission, readmission/reoperation rates, and oncological surgical outcomes (resection margins, lymph node harvest). The study aims to provide initial safety and feasibility data to support the regulatory pathway for the RonovoTM platform in Latin America.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07632638 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify